| Schedule of financial assets and liabilities measured at fair value on a recurring basis |
The following tables set forth the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements as of March 31, 2026 using: |
|
|
Quoted Prices in |
|
Significant Other |
|
Significant |
|
|
|
|
|
Active Markets for |
|
Observable |
|
Unobservable |
|
|
|
|
|
Identical Assets |
|
Inputs |
|
Inputs |
|
|
|
|
|
(Level 1) |
|
(Level 2) |
|
(Level 3) |
|
Total |
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
|
$ |
49,835 |
|
$ |
— |
|
$ |
— |
|
$ |
49,835 |
U.S. treasury bills |
|
|
25,505 |
|
|
— |
|
|
— |
|
|
25,505 |
Total cash equivalents |
|
|
75,340 |
|
|
— |
|
|
— |
|
|
75,340 |
Exarafenib milestone asset (Note 6) |
|
|
— |
|
|
— |
|
|
3,704 |
|
|
3,704 |
Investment in equity securities |
|
|
494 |
|
|
— |
|
|
— |
|
|
494 |
Castle Creek PRV Interest (Note 4) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Castle Creek warrants (Note 4) |
|
|
— |
|
|
— |
|
|
709 |
|
|
709 |
Total financial assets |
|
$ |
75,834 |
|
$ |
— |
|
$ |
4,413 |
|
$ |
80,247 |
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Exarafenib milestone contingent consideration (Note 6) |
|
$ |
— |
|
$ |
— |
|
$ |
3,704 |
|
$ |
3,704 |
Total financial liabilities |
|
$ |
— |
|
$ |
— |
|
$ |
3,704 |
|
$ |
3,704 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements as of December 31, 2025 using: |
|
|
Quoted Prices in |
|
Significant Other |
|
Significant |
|
|
|
|
|
Active Markets for |
|
Observable |
|
Unobservable |
|
|
|
|
|
Identical Assets |
|
Inputs |
|
Inputs |
|
|
|
|
|
(Level 1) |
|
(Level 2) |
|
(Level 3) |
|
Total |
Assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents: |
|
|
|
|
|
|
|
|
|
|
|
|
Money market funds |
|
$ |
41,810 |
|
$ |
— |
|
$ |
— |
|
$ |
41,810 |
U.S. treasury bills |
|
|
6,330 |
|
|
— |
|
|
— |
|
|
6,330 |
Total cash equivalents |
|
|
48,140 |
|
|
— |
|
|
— |
|
|
48,140 |
Exarafenib milestone asset (Note 6) |
|
|
— |
|
|
— |
|
|
3,600 |
|
|
3,600 |
Investment in equity securities |
|
|
382 |
|
|
— |
|
|
— |
|
|
382 |
Castle Creek PRV Interest (Note 4) |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
Castle Creek warrants (Note 4) |
|
|
— |
|
|
— |
|
|
697 |
|
|
697 |
Total financial assets |
|
$ |
48,522 |
|
$ |
— |
|
$ |
4,297 |
|
$ |
52,819 |
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Exarafenib milestone contingent consideration (Note 6) |
|
$ |
— |
|
$ |
— |
|
$ |
3,600 |
|
$ |
3,600 |
Share-based liability (Note 12) |
|
|
— |
|
|
— |
|
|
3,197 |
|
|
3,197 |
Total financial liabilities |
|
$ |
— |
|
$ |
— |
|
$ |
6,797 |
|
$ |
6,797 |
|